Figure 1
From: Targeting HER-3 to elicit antitumor helper T cells against head and neck squamous cell carcinoma
HER-3 upregulation on the surface of tumor cells by a pan HER family inhibitor.
(A) HER-3 expression on tumor cells was assessed using flowcytometry. Head and neck squamous cell carcinoma (HNSCC) cell lines (SAS, HPC92Y, HSC3, HSC4 and Sa-3), lung cancer cell lines (Calu-1 and Lu65) and a colon cancer cell line (WiDr) cell lines expressed HER-3. Jurkat cells and peripheral blood mononuclear cells (PBMCs) from healthy donor were used as negative controls. The dead cells and the doublets were eliminated by FSC/SSC gating before the analysis. Black lines: Isotype control; Red lines: anti-HER-3 antibody. (B,C) HER-3 expression on SAS, HPC92Y and Calu-1 cells was evaluated after 48-h pre-incubation with dacomitinib (1 μM). Black: isotype control, red: an anti-HER-3 antibody, blue: addition of dacomitinib. Mean fluorescence intensity (MFI) fold changes in the isotype antibody group are shown in the graph: *p < 0.05. Columns: means of triplicate measurements, error bars: SEM. The dead cells and the doublets were eliminated by FSC/SSC gating before the analysis. The results shown are representative of 3 separate experiments.
